Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability

Neuropsychopharmacology

Volumn 34, Issue 3, 2009, Pages 585-592

  Landén, Mikael ^a   Erlandsson, Helena ^b   Bengtsson, Finn ^c   Andersch, Björn ^b   Eriksson, Elias ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Irritability; Onset of action; Paroxetine; Premenstrual dysphoric disorder; Premenstrual syndrome; Serotonin reuptake inhibitor

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRRITABILITY; LUTEAL PHASE; NAUSEA; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE MOOD; LUTEAL PHASE; MENSTRUAL CYCLE; NAUSEA; PAROXETINE; PREMENSTRUAL SYNDROME; SELF ASSESSMENT (PSYCHOLOGY); SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 58149471983     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.86     Document Type: Article

References (43)

1. Artigas F, Romero L, de Montigny C, Blier P (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378-383.
2. Brzezinski AA, Wurtman JJ, Wurtman RJ, Gleason R, Greenfield J, Nader T (1990). d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol 76: 296-301.
3. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R (1999). Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 14: 681-685.
4. Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K et al (2002). Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 100: 435-444.
5. Davidson JR, Landerman LR, Farfel GM, Clary CM (2002). Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol Med 32: 661-670.
6. Eriksson E, Andersch B, Ho HP, Landén M, Sundblad C (2002). Diagnosis and treatment of premenstrual dysphoria. J Clin Psychiatry 63: 16-23.
7. Eriksson E, Lisjö P, Sundblad C, Andersson K, Andersch B, Modigh K (1990). Effect of clomipramine on premenstrual syndrome. Acta Psychiatr Scand 81: 87-88.
8. Freeman EW (2003). Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 28(Suppl 3): 25-37.
9. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S (2004). Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161: 343-351.
10. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ (1989). The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab 68: 632-637.
11. Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J (2004). Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50: 200-205.
12. Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28(Suppl 3): 1-23.
13. Halbreich U, Smoller JW (1997). Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 58: 399-402.
14. Ho HP, Olsson M, Westberg L, Melke J, Eriksson E (2001). The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability? Neuropsychopharmacology 24: 502-510.
15. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ (1999). Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, cross-over study. Arch Fam Med 8: 328-332.
16. Kahn RS, Wetzler S, van Praag HM, Asnis GM, Strauman T (1988). Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 25: 101-104.
17. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC et al (1998). Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 155: 373-379.
18. Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA (2006). Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 67: 1624-1632.
19. Landén M, Eriksson E (2003). How does premenstrual dysphoria relate to anxiety disorders? Depress Anxiety 17: 122-129.
20. Landén M, Nissbrandt H, Allgulander C, Sörvik K, Ysander C, Eriksson E (2006). A placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 32: 153-161.
21. Lichtenberg P, Shapira B, Blacker M, Gropp C, Calev A, Lerer B (1992). Effect of fenfluramine on mood: a double-blind placebo-controlled trial. Biol Psychiatry 31: 351-356.
22. McBride PA, DeMeo MD, Sweeney JA, Halper J, Mann JJ, Shear MK (1992). Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. Biol Psychiatry 31: 19-34.
23. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M (2002). Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 24: 417-433.
24. Muller U, Murai T, Bauer-Wittmund T, von Cramon DY (1999). Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 13: 805-811.
25. Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS (1998). Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 10: 453-455.
26. Reis M, Åberg-Wistedt A, Ågren H, Höglund P, Åkerblad AC, Bengtsson F (2004). Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 19: 283-291.
27. Reist C, Nakamura K, Sagart E, Sokolski KN, Fujimoto KA (2003). Impulsive aggressive behavior: open-label treatment with citalopram. J Clin Psychiatry 64: 81-85.
28. Rothman RB, Baumann MH (2002). Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95: 73-88.
29. Rubey RN, Johnson MR, Emmanuel N, Lydiard RB (1996). Fluoxetine in the treatment of anger: an open clinical trial. J Clin Psychiatry 57: 398-401.
30. Rutter JJ, Auerbach SB (1993). Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J Pharmacol Exp Ther 265: 1319-1324.
31. Shin JG, Kim KA, Yoon YR, Cha IJ, Kim YH, Shin S (1998). Rapid simple high-performance liquid chromatographic determination of paroxetine in human plasma. J Chromatogr B Biomed Sci Appl 25: 452-456.
32. Sloan RL, Brown KW, Pentland B (1992). Fluoxetine as a treatment for emotional lability after brain injury. Brain Inj 6: 315-319.
33. Steiner M, Born L (2000). Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 15(Suppl 3): S5-17.
34. Steiner M, Hirschberg AL, Bergeron R, Holland F, Gee MD, Van Erp E (2005). Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 193: 352-360.
35. Steiner M, Korzekwa M, Lamont J, Wilkins A (1997). Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 33: 771-774.
36. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R et al (1995). Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 332: 1529-1534.
37. Stone AB, Pearlstein TB, Brown WA (1991). Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 52: 290-293.
38. Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR (1997). Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 82: 1220-1228.
39. Sundblad C, Hedberg MA, Eriksson E (1993). Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 9: 133-145.
40. Sundblad C, Modigh K, Andersch B, Eriksson E (1992). Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 85: 39-47.
41. Targum SD, Marshall LE (1989). Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28: 295-306.
42. Waldinger MD, Zwinderman AH, Olivier B (2004). On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol 46: 510-515; discussion 516.
43. Yonkers KA, Holthausen GA, Poschman K, Howell HB (2006). Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol 26: 198-202.